Navigation Links
Ther-Rx Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level
Date:2/3/2009

ST. LOUIS, Feb. 3 /PRNewswire/ -- Ther-Rx Corporation, a subsidiary of KV Pharmaceutical Company (NYSE: KVa/KVb), is issuing a voluntary nationwide recall of prescription prenatal and iron supplement nutritionals as identified below (all lots within their expiration dates) at a wholesale level. The Company is taking this action as a precautionary measure, because the products may have been manufactured under conditions that did not sufficiently comply with current Good Manufacturing Practice (cGMP).

Patients who may have these products in their possession should continue to take them in accordance with their prescriptions, as the risk of suddenly stopping needed medication may place patients at risk. Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using these products, or to obtain replacement medications or prescriptions.

    Products Recalled to the Wholesale Level:

    Prescription Iron Supplement Products:

    Chromagen(R) Caplet                     Chromagen(R) FA Caplet
    Chromagen(R) Forte Caplet               Encora(R) Capsule
    Niferex(R) Gold Tablet                  Niferex(R) 150 Forte Capsule
    Repliva 21/7(R) Tablet

    Prescription Prenatal Vitamin Products:

    PreCare(R) Chewable Tablet              PreCare(R) Conceive Tablet
    PreCare Premier(R) Tablet               PremesisRx(R) Tablet
    PrimaCare(R) Capsule/Tablet             PrimaCare(R) Advantage(TM)
    PrimaCare(R) ONE Capsule                 Capsule/Tablet

Any retail customer inquiries related to this action should be addressed to Ther-Rx Customer Service at 877-567-7676, or faxed to Ther-Rx Customer Service at (314) 646-3701, or e-mailed to info@ther-rx.com. Representatives are available Monday through Friday, 8 am to 5 pm CST.

Ther-Rx Corporation has initiated recall notifications to wholesalers nationwide who received any inventory of the recalled products, with instructions for returning the recalled products. Patients with questions about the recall should call the telephone number above, or contact their healthcare providers.

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA). At this time, the Company is unable to determine when distribution of these products will resume.

Any adverse reactions experienced with the use of these products should also be reported to the FDA's MedWatch Program by phone at 1-800-FDA-1088, by fax at 1-800-FDA-0178, by mail at MedWatch, FDA, 5600 Fishers Lane, Rockville, MD 20852-9787, or on the MedWatch website at www.fda.gov/medwatch.

The recall announcement is posted on www.kvpharmaceutical.com.

About KV Pharmaceutical Company

KV Pharmaceutical Company is a fully integrated specialty pharmaceutical company that develops, manufactures, markets, and acquires technology-distinguished branded and generic/non-branded prescription pharmaceutical products. The Company markets its technology distinguished products through ETHEX Corporation, a national leader in generic pharmaceuticals, and Ther-Rx Corporation, its branded drug subsidiary.


'/>"/>
SOURCE Ther-Rx Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
2. Brooke Franchise Corporation Announces Selected July Results
3. MedThink Communications Retained by NanoBio Corporation
4. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
5. Dana Corporation, Inc. Enters Into Settlement Agreement With Dana Retiree Committee
6. Memry Corporation Announces Fiscal Fourth Quarter and 2007 Year End Earnings Release and Conference Call
7. Somanetics Corporation to Release Third Quarter 2007 Financial Results and Host Conference Call September 19
8. LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
9. DTI Medical Corporation Announces Reverse Split and Other Corporate Developments
10. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
11. AGA Medical Corporation Receives Approval for the AMPLATZER Muscular Ventricular Septal Defect Occluder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... CarriersEdge, providers of online ... new suite of Driver Wellness courses. Offered in three modules, the courses can be ... so fleets can educate drivers about how to stay healthy on the road. , ...
(Date:12/6/2016)... ... December 06, 2016 , ... After 30 years with The ... has announced her retirement from HASA at the end of 2016. ... 4,000 individuals and families with hearing and speech services. She has overseen the ...
(Date:12/6/2016)... ... December 06, 2016 , ... SPH Analytics recently ranked fifth ... is based on reported data for 2015 performance and recognizes SPHA for its ... clinically integrated networks, and many of the nation’s leading health plans. , “In ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... The NALA, ... the Teddy Bear Cancer Foundation (TBCF), a nonprofit 501(C)(3) organization providing financial ... and San Luis Obispo counties. To assist TBCF, the NALA recently hosted a Thanksgiving ...
(Date:12/6/2016)... ... December 06, 2016 , ... Healthcare ... federal healthcare regulations at the 7th annual Health IT Leadership Summit, to be ... acting administrator for the Centers for Medicare & Medicaid Services (CMS), will be ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... SAN DIEGO , Dec. 6, 2016 /PRNewswire/ ... leading RNA medicines company, announced today that it ... to develop RNA-based therapeutics for the treatment of ... Arcturus, wholly-owned therapeutic delivery platform LUNAR™ and UNA ... "Given Takeda,s long-standing commitment to and ...
(Date:12/6/2016)... 6, 2016  Regulus Therapeutics Inc. (NASDAQ: ... discovery and development of innovative medicines targeting microRNAs, ... its R&D day, held in New ... an anti-miR targeting microRNA-27 (miR-27) for the treatment ... an anti-miR targeting microRNA-17 (miR-17) for the treatment ...
(Date:12/6/2016)... , Dec. 6, 2016 A new study ... 340B (AIR 340B) projects the 340B Drug Pricing Program will ... which time it is expected to exceed $23 billion in ... see 340B purchases surpass current Medicare Part B drug reimbursement ... new study – based on analysis of data on total ...
Breaking Medicine Technology: